|
Feb 28
|
Immune-Onc doses first subject in trial of IO-108 for HCC
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 12
|
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 12
|
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 10
|
Is Roche Holding AG (RHHBY) The Best Annual Dividend Stock To Buy Now?
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Oct 11
|
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
|
|
Oct 11
|
Roche’s VENTANA CLDN18 assay gains CE mark
|
|
Oct 11
|
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
|
|
Oct 11
|
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Oct 10
|
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Oct 10
|
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
|
|
Oct 10
|
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
|
|
Oct 10
|
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
|
|
Oct 9
|
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ...
|
|
Oct 9
|
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...
|
|
Oct 9
|
Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ...
|
|
Oct 8
|
Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public
|
|
Oct 7
|
ONCY Stock Up on Regulatory Update From Breast Cancer Program
|
|
Oct 7
|
Scholar Rock scores with ‘surprise’ success in SMA drug study
|